SAVA
Cassava Sciences Inc
NASDAQ: SAVA · HEALTHCARE · BIOTECHNOLOGY
$1.45
+0.69% today
Updated 2026-04-30
Market cap
$142.03M
P/E ratio
—
P/S ratio
2.54x
EPS (TTM)
$-2.22
Dividend yield
—
52W range
$1 – $5
Volume
0.5M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D4.7
Valuation
C—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$8.00
+451.72%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-10.25M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $-1800.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-72.47M | $-97.22M | $-24.34M | $-90.97M | $-12.54M |
| EPS | — | — | — | — | $-2.22 |
| Free cash flow | $-80.23M | $-82.44M | $-117.03M | $-32.83M | $-10.25M |
| Profit margin | 4,026,222.22% | — | — | — | — |
Peer comparison
Smart narrative
Cassava Sciences Inc trades at $1.45. Our Smart Value Score of 36/100 indicates the stock is weak.
Frequently asked questions
What is Cassava Sciences Inc's stock price?
Cassava Sciences Inc (SAVA) trades at $1.45.
Is Cassava Sciences Inc overvalued?
Smart Value Score 36/100 (Grade D, Sell).
What is the price target of Cassava Sciences Inc (SAVA)?
The analyst target price is $8.00, representing +451.7% upside from the current price of $1.45.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.54x
ROE-0.89%
Beta-1.09
50D MA$3.21
200D MA$2.38
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—